Advertisement

Ist die Behandlung mit BCG eine Immuntherapie?

  • S. Prescott
  • S. J. Hawkyard
  • A. M. Jackson
  • K. James
  • G. D. Chisholm
Conference paper

Zusammenfassung

Die Verabreichung des Impfstoffs Bacille-Calmette-Guérin (BCG) führt zu einer Stimulation des Immunsystems (Davies 1982); doch stellt sich die Frage, ob die vorteilhafte antitumorale Wirkung der intravesikalen BCG-Behandlung immunologischer Art ist und welche Immunmechanismen an dieser Reaktion beteiligt sind. Dies kann zur Lösung praktischer Probleme wie der Wahl des optimalen Behandlungsverlaufs und Indikation zur Fortführung der Therapie beitragen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alroy J, Pauli BU, Hayden JE, Gould VE (1979) Cytoplasmic lumina in bladder carcinomas. Hum Pathol 10: 549–555PubMedCrossRefGoogle Scholar
  2. Bast RC, Zbar B, Borsos T, Rapp HJ (1974) BCG and cancer (2 parts). N Engl J Med 290: 1413–1420PubMedCrossRefGoogle Scholar
  3. Bast RC, Zbar B, Borsos T, Rapp HJ (1974) BCG and cancer (2 parts). N Engl J Med 290: 1458–1469 Thoa290: 1458–1469PubMedCrossRefGoogle Scholar
  4. Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacille Calmette Guerin by bladder tumour cells. J Urol 145: 1316–1324PubMedGoogle Scholar
  5. Böhle A, Nowc Ch, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumour necrosis factor in the urine of patients after intravesical bacillus Calmette Guerin immunotherapy. J Urol 144: 59–64PubMedGoogle Scholar
  6. Coe JE, Feldman JD (1966) Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology 10 (2): 127–36PubMedGoogle Scholar
  7. Connolly JG (1983) Letter to Editor re Immunotherapy of superficial bladder cancer. J Urol 130: 368PubMedGoogle Scholar
  8. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ (1984 a) The detailed distribution of HLA-ABC antigens in normal human organs Transplantation 38: 287–292PubMedCrossRefGoogle Scholar
  9. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ (1984 a) The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 38: 293–297 ThoaThe detailed distribution of MHC Class II antigens in normal human organs. Transplantation 38: 293–297PubMedCrossRefGoogle Scholar
  10. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ (1984b) The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 38: 293–297PubMedCrossRefGoogle Scholar
  11. Davies M (1982) Bacillus Calmette Guerin as an anti tumour agent: the interaction with cells of the mammalian immune system. Biochim Biophys Acta 651: 143–174PubMedGoogle Scholar
  12. Hanna MG, Zbar B, Rapp HJ (1972) Histopathology of tumour regression after intralesional injection of Mycobacterium bovis ii, Comparative effects of Vaccinia virus, Oxalozone and Turpentine. J Natl Cancer Inst 48: 1697–1703PubMedGoogle Scholar
  13. Hawkyard SJ, James K, Prescott S, Jackson AM, Ritchie AWS, Chisholm GD (1991) The effects of recombinant interferon-gamma on a panel of human bladder cancer cell lines. J Urol 145: 1078–1081PubMedGoogle Scholar
  14. Hawkyard SJ, James K, Prescott S, Jackson AM, Ritchie AWS, Chisholm GD (1992) The growth inhibitory effects of interferon gamma on bladder cancer cells. J Urol 147: 1399–1403PubMedGoogle Scholar
  15. Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL (1985) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical Bacillus Calmette-Guérin. J Urol 135: 268–271Google Scholar
  16. Leake ES, Ockers JR, Myrvik QN (1976) In vitro interactions of the BCG and Ravenol strains of Mycobacterium bovis with rabbit macrophages: adherence of the phagosomal membrane to the bacterial cell wall and the problem of the peribacillary space. J Reticuloendothelial Soc 22: 129–147Google Scholar
  17. Prescott S, James K, Hargreave TB, Busutti A, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63: 264–269PubMedCrossRefGoogle Scholar
  18. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248–1251PubMedGoogle Scholar
  19. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147, 1636–1642PubMedGoogle Scholar
  20. Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG mediated antitumour activity. J Urol 137: 155–158PubMedGoogle Scholar
  21. Rooke GAW, Steele J, Fraher L, Barker S, Karmali R, O’Riordan J, Stanford J (1986) Vitamin D3, gamma interferon and control of proliferation of Mycobacterium tuberculosis by human monocytes Immunology 57: 159Google Scholar
  22. Sarzotti M, Baron S, Tyring SK, Klimpel GR (1986) Interferon mediated protection of B16melanoma cells from cytotoxicity by activated macrophages. Cell Immunol 100: 280–287PubMedCrossRefGoogle Scholar
  23. Schamhart DHJ, Kurth K (1990) Detection of urinary IL-6 during intravesical BCG therapy. J Urol 143: 321A (Abstr 531)Google Scholar
  24. Schwartz R, Momburg F, Moldenhauer G, Dörken B, Schirrmacher V (1985) Induction of HLA Class II antigen expression on human carcinoma cell lines by interferon-gamma. Int J Cancer 35: 245–250PubMedCrossRefGoogle Scholar
  25. Spector WG, Marianayagam Y, Ridley MJ (1982) The role of antibody in primary and reinfection BCG granulomas of rat skin. Journal of Pathology 136 (1): 41–57PubMedCrossRefGoogle Scholar
  26. Trinchieri G, Perussia B (1985) Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6: 131–136CrossRefGoogle Scholar
  27. Welsh RM, Karre K, Hanson M, Kunkel LA, Kiessling RW (1981) Interferon mediated protection of normal and tumour target cells aginst lysis by mouse natural killer cells. J Immunol 126: 219–225PubMedGoogle Scholar
  28. Zinkernagel RM, Docherty PC (1979) MHC cytotoxicT-cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv Immunol 27: 51–177PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • S. Prescott
  • S. J. Hawkyard
  • A. M. Jackson
  • K. James
  • G. D. Chisholm

There are no affiliations available

Personalised recommendations